Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
The QRS interval of 56 out of 75 (74.7%) HIV-infected, drug-experienced patients (66.7% men) increased during treatment with boosted or unboosted atazanavir by a median 5 ms (interquartile range 0-9; P < 0.0001); the PR and the QTc intervals did not change significantly. New asymptomatic bundle branch blocks were observed in four patients; one subject with a baseline first-degree atrioventricular block developed symptomatic bradyarrhythmia while receiving atenolol. The electrocardiographic monitoring of patients treated with atazanavir seems advisable.
Gianotti
Nicola
N
Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy.
Guffanti
Monica
M
Galli
Laura
L
Margonato
Alberto
A
Chiaravalli
Giulia
G
Bigoloni
Alba
A
Lazzarin
Adriano
A
Castagna
Antonella
A
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000069446:Atazanavir Sulfate; D002037:Bundle-Branch Block / Q000139:chemically induced*; D016903:Drug Monitoring / Q000379:methods; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate